Biocon India Limited

Small-to-medium sized pharmaceutical and biotech companies are positioned to bring 50 percent of new drug molecules to market in the next decade. With escalating R&D costs and the long path to new medicine, these companies are forced to view outsourcing or contract services as an important part of their manufacturing strategy.

Biocon leverages its India cost-base together with its extensive expertise and technology platforms to offer competitive, high quality, custom manufacturing services to a global clientele. Biocon’s full set of customer manufacturing capabilities, include mammalian cell culture fermentation, microbial cell culture fermentation, synthetic chemistry. The facility has been inspected by various international regulators including the USFDA, EU Inspectors, BfArM and Anvisa.

Biocon is continuously leveraging its rich pool of research talent to pursue its mid-to-long-term goals to collaboratively develop MAbs (Monoclonal Antibodies) Human Insulin and their analogs and other novel drug delivery systems-based proteins either in-house or in partnership with other companies. Such symbiotic co-development activities will enable Biocon to out-license the researched product for global markets. As we focus our resources on various R&D programs in key disease segments, we believe out-licensing is the way forward and will be a significant future growth driver for the company.

High levels of innovation and increased productivity are imperatives of the global healthcare industry. To meet this twin demand, Syngene, our custom research organisation and Clinigene, our clinical research company works in partnership with complementary biotechnology and pharmaceutical companies. We believe these partnerships will positively impact all phases of our discovery portfolio. We are also confident that our well-structured alliances will mitigate the risk of discovery and encourage a stimulating environment of continuous knowledge creation.